Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Osteoarthritis

This article was originally published in The Tan Sheet

Executive Summary

Novel blend of fatty acid esters (CMC) "may improve the quality of life in patients with [osteoarthritis]," poster presented at FASEB meeting by R.R. Barathur, ClinCyte, et al., states. Double-blind, placebo-controlled, 60-day study of 100 subjects found that after 30 days subjects taking a CMC capsule daily showed a reduction in the Lequesne's Disease Severity Index, identified by knee pain, stiffness and function. The CMC group also displayed "significant improvements in flat ground walking and traversing up and down stairs"
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS092404

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel